ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. have announced a major milestone in their collaboration, successfully demonstrating the feasibility of a molecular diagnostic test for Mycobacterium Tuberculosis (MTB) that can be conducted using a saliva sample.
MTB is a highly contagious airborne disease that caused over 10 million infections worldwide in 2021, resulting in 1.6 million deaths. Alarmingly, an estimated 4 million infections (40% of all cases) remain undiagnosed and untreated, presenting a serious healthcare challenge. Current diagnosis methods, such as smear microscopy, rely on sputum samples and are often limited in remote areas or when diagnosing certain patient populations.
In response, the World Health Organization (WHO) has recommended the use of molecular diagnostic tests that can utilize alternative sample types like saliva, thereby improving testing accessibility. ReadyGo and Gemina now plan to proceed to full product development, leveraging the Geo platform. This innovative solution will provide results within 30 minutes, making it accessible anywhere and at an affordable cost.
Ben Cobb, CEO of ReadyGo Diagnostics, commented: “I’m thrilled about our continued progress and partnership with Gemina to establish a tuberculosis diagnostic platform that can use saliva as the primary sample. We understand the pressing need for a triaging test that can replace smear microscopy at an affordable price point, particularly in resource-constrained settings.”
Brian Firth, CEO of Gemina, added: “I’m delighted to be seeing such significant results so quickly from our partnership with ReadyGo Diagnostics. Our goal is to create better diagnostic tests for managing patients with tuberculosis, and the fact that we have proven feasibility of detecting TB in saliva opens the door to a fundamental improvement in human health and a contribution to eradicating TB worldwide.”
ReadyGo Diagnostics is a rapidly growing diagnostics company that designs, develops and commercialises novel sample collection devices and diagnostic platforms. Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness.
Today, ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. are thrilled to announce a significant milestone in their collaboration; the successful feasibility of a molecular diagnostic test for Mycobacterium Tuberculosis (MTB) that can be conducted using a saliva sample.
MTB is a highly contagious airborne disease that caused over 10 million infections worldwide in 2021, resulting in 1.6 million deaths. Alarmingly, an estimated 4 million infections (40% of all cases) remain undiagnosed and untreated, posing significant challenges to disease control initiatives. In response, the World Health Organization (WHO) has recommended the use of molecular diagnostic tests that can utilize alternative sample types like saliva, thereby improving testing accessibility.
ReadyGo and Gemina now plan to proceed to full product development, leveraging the Geo platform. This innovative solution will provide results within 30 minutes, making it accessible anywhere and at an affordable cost.
Ben Cobb, CEO of ReadyGo Diagnostics, stated: “I’m thrilled about our continued progress and partnership with Gemina to establish a tuberculosis diagnostic platform that can use saliva as the primary sample. We understand the pressing need for a triaging test that can replace smear microscopy at an affordable price point, particularly in resource-constrained settings.”
Brian Firth, CEO of Gemina, added: “I’m delighted to be seeing such significant results so quickly from our partnership with ReadyGo Diagnostics. Our goal is to create better diagnostic tests for managing patients with tuberculosis, and the fact that we have proven feasibility of detecting TB in saliva opens the door to a fundamental improvement in human health and a contribution to eradicating TB worldwide.”
ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. are pleased to announce the successful feasibility of a molecular diagnostic test for Mycobacterium Tuberculosis (MTB) that can be conducted using a saliva sample. This breakthrough product is expected to have a profound impact on how TB is detected, particularly in countries such as India, Indonesia, and other affected regions around the world. The team plans to launch an MTB Screening Test in 2024, which will replace smear microscopy with a simple saliva sample, and are aiming to introduce a compact laboratory instrument that will retail for under $1000, with a per-test cost of $5, enabling field testing near patients.
The post SAMPLES
ReadyGo Diagnostics and Gemina Laboratories Demonstrate Feasibility of Mycobacterium Tuberculosis (MTB) Diagnosis Using Saliva Samples first appeared on BusinessMole.
